Acurx Pharmaceuticals (ACXP) vs Alzamend Neuro (ALZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acurx Pharmaceuticals is the larger company by market cap ($6.9 million vs $6.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | ALZN |
|---|---|---|
| Share price | $1.25 | $1.34 |
| Market cap | $6.95M | $6.47M |
| 1-day change | -3.85% | -2.19% |
| EPS (TTM) | $-2.67 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $2.68 |
| 52-week low | $1.23 | $0.84 |
| Distance from 52-week high | -84.34% | -50.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1260.00% | +1840.30% |
| Average volume | 125.08K | 88.67K |
| Shares outstanding | 5.56M | 4.83M |
| Employees | 4 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Healthcare · Biotechnology · 4 employees
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Healthcare · Biotechnology · 4 employees
ACXP vs ALZN FAQ
Which is bigger, Acurx Pharmaceuticals or Alzamend Neuro?
Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $6.95M compared with $6.47M for Alzamend Neuro (ALZN).
Are Acurx Pharmaceuticals and Alzamend Neuro in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.